InDevR Inc., an innovative life science company specializing in enhancing biopharmaceutical and vaccine production, recently announced that it has launched its potency assay called VaxArray, a re-branded version of InDevR’s previously Influenza Titer on Chip or Flu-ToC.
VaxArray Influenza potency assay is designed as a multiplexed immunoassay to treat hemagglutinin (HA) quantification. The vaccine uses a series of subtype-specific, broadly reactive monoclonal capture antibodies that are printed in a microarray format.“Time to market in the vaccine industry is critical. With VaxArray customers save valuable time with an off-the-shelf potency assay that allows them to assess HA concentration and stability within hours rather than days, even during the early stages of development,” InDevR Chief Executive Officer Kathy Rowlen said. “We have re-branded Flu-ToC to better reflect the platform flexibility. While VaxArray Influenza is the first potency assay we’ve launched, the technology will be useful for other vaccines as well. Animal vaccines and vaccines against potential pandemic influenza viruses represent another great market opportunity for this product and we intend to pursue those applications next.”
Director of Analytical Development
Michèle Dargis had early access to the technology.
“Although we are still evaluating this promising new technology, we are optimistic that the VaxArray Influenza potency assay will lead to a valid measurements of hemagglutinin in plant-based flu VLP vaccines,” Dargis said.